This site is intended for health professionals only

Published on 28 May 2012

Share this story:
Twitter
LinkedIn

BMI unveils gene test for clopidogrel resistance

teaser

BMI The London Independent Hospital’s cardiology team today announced that it has become the first UK hospital to unveil Spartan RX, an all-in-one genetic test used to identify patients who are resistant to the blood-thinning drug, clopidogrel. 

 

Patients who are resistant to clopidogrel, the second most prescribed medication in the world, are at an increased risk of suffering from recurrent heart problems, and sometimes heart attacks, following a cardiac stent procedure. 

 

Spartan RX identifies the gene, CYP2C19*2, which is present in 30 per cent of the world’s population. 

 

There is evidence that having this gene can impair the delivery of the blood thinning medication clopidogrel[i].  

 

In the UK, around 85,000 patients each year have stents inserted into their diseased arteries to help restore blood flow to the heart.

 

BMI



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn